NovaBridge Biosciences Gestione
Criteri Gestione verificati 1/4
Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.
Informazioni chiave
Srishti Gupta
Amministratore delegato
n/a
Compenso totale
| Percentuale dello stipendio del CEO | n/a |
| Mandato del CEO | less than a year |
| Proprietà del CEO | n/a |
| Durata media del management | less than a year |
| Durata media del Consiglio di amministrazione | 6.8yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Nuova narrativa • Aug 21
Aging Population And Oncology Pipeline Will Support Long Term Therapy Demand
Catalysts About NovaBridge Biosciences NovaBridge Biosciences focuses on acquiring and developing clinical stage therapies in oncology and ophthalmology, with an emphasis on translating promising science into approved medicines. What are the underlying business or industry changes driving this perspective?Seeking Alpha • Jul 04
NovaBridge: Rebranded, Repackaged, But Far From De-Risked
Summary NovaBridge (NBP) is rated Sell due to limited market opportunity, intense competition, and high cash burn overshadowing its cash-rich balance sheet. Givastomig, the lead asset, faces entrenched competitors, a small addressable market, and only a 50% ownership stake for NBP. Risk-adjusted NPV for givastomig is negative; intrinsic equity value is $0.88/share, reflecting expected dilution and future cash needs. Pipeline optionality exists but is speculative, not wholly owned, and unlikely to offset the risks in the core gastric/GEA indication. Read the full article on Seeking AlphaArticolo di analisi • May 27
Companies Like NovaBridge Biosciences (NASDAQ:NBP) Can Afford To Invest In Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Articolo di analisi • Dec 31
NovaBridge Biosciences (NASDAQ:NBP) Shares Could Be 41% Below Their Intrinsic Value Estimate
Key Insights Using the 2 Stage Free Cash Flow to Equity, NovaBridge Biosciences fair value estimate is US$6.72...Seeking Alpha • Feb 18
I-Mab: Trading Below Net Cash With Multiple Upside Options
Summary I-Mab Biopharma has signed an agreement to divest its assets and business operations in China, becoming a US-based biotech company. The divesting will provide I-Mab with a healthy balance sheet, over $400 million in cash, and the potential to receive up to $80 million in cash consideration from its divested China operation. I-Mab's core assets will consist of three global Immuno-Oncology programs, including uliledlimab, which has shown promising Phase 2 NSCLC clinical trial data. Read the full article on Seeking AlphaArticolo di analisi • Feb 08
We're Keeping An Eye On I-Mab's (NASDAQ:IMAB) Cash Burn Rate
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Seeking Alpha • Sep 27
I-Mab: Another CD47 Inhibitor Biotech With Great Potential
Summary Clearance from China was received to initiate a phase 3 registrational study using Lemzoparlimab for high-risk MDS patients; trial initiation is expected in Q4 of 2022. Results from phase 2 studies using uliledlimab for the treatment of patients with non-small cell lung cancer are expected in Q4 of 2022. Two other products in the pipeline nearing BLAs in China are felzartamab for multiple myeloma and eftansomatropin alfa for growth hormone deficiency. The global Myelodysplastic Syndrome market is expected to reach $3.26 billion in 2022. I-Mab (IMAB) is a great speculative biotech play to look into. The reason why I state that is because it has a drug known as Lemzoparlimab. The goal is to initiate a phase 3 study using this drug in combination with azacitidine for the treatment of 1st-line myelodysplastic syndrome ((MDS)). The biotech had a great end of phase 2 meeting with Chinese authorities and received the go ahead to initiate a phase 3 study for this program. This late-stage study is expected to be initiated in Q4 of 2022. In addition, the company is also exploring a few other indications with the use of Lemzoparlimab. It has developed a partnership with AbbVie (ABBV) to develop new CD47 antibodies. If such a partnership makes it all the way through all the milestones, then I-Mab would be entitled to receive up to $1.295 billion in milestone payments. The biotech is also in the process of initiating another phase 3 registrational trial as well. This involves the use of its differentiated CD73 antibody uliledlimab being developed to treat patients with non-small cell lung cancer ((NSCLC)). It also has plans to initiate a phase 3 study in the United States targeting other cancer types, however, it hopes to do so through other drugs besides PD-1 inhibitors within the next 12 months. It will also make available results from the ongoing phase 2 study of uliledlimab for the treatment of patients with NSCLC by the end of 2022. The main thing you probably want to know is, what is its intended goal? It believes it could have 5 clinical-stage assets with at least three Biologic Licensing Applications (BLAs) within the next 3 years. Then, it has a bispecific antibody known as TJ-CD4B, which is being developed to treat patients with various types of solid tumors. This drug is currently being explored in a phase 1 study. One key thing to note is that I-Mab is exploring partnership opportunities for uliledlimab and TJ-CD4B, which could also create shareholder value as well. CD47 Inhibitor With Proof Of Concept Already Established The first program to go over involves the use of Lemzoparlimab for the treatment of patients with Myelodysplastic Syndrome. Myelodysplastic Syndrome ((MDS)) involves a group of cancers that keep your blood stem cells from maturing into healthy blood cells. However, MDS can also cause other problems as well, ranging from developing Acute Myeloid Leukemia ((AML)) or anemia (lack of healthy red blood cells to carry oxygen), frequent infections, and bleeding episodes which may not stop. Healthy red blood cells are made in the soft spongy area known as the bone marrow. If such production doesn't work, then red blood cells die in the bone marrow, or if they reach out to parts of your body they die off. When red blood cells die in the bone marrow, there is no room for the healthy red blood cells to exist. This effect leads to serious problems, which is why MDS needs to be taken care of. The global Myelodysplastic Syndrome market is expected to reach $3.26 billion in 2022 and grow at about 9.3% CAGR thereafter until 2030. There are several symptoms that these patients experience as well, which are as follows: You are tired/weak Skin becomes pale Bleed more often Frequent infections Frequent fevers. The goal for I-Mab is to advance Lemzoparlimab to a phase 3 study in treating newly diagnosed higher-risk MDS patients in Q4 of 2022. Of course, it already received authorization from the CDE and NMPA (Chinese authority agencies) to begin such a study. It expects to initiate this phase 3 registrational study before the end of this year, likely Q4 of 2022. The main reason why I'm talking about this program is because it is the furthest along. If a phase 3 study starts by the end of this year for Lemzoparlimab for newly diagnosed MDS patients, then results should be out within a few years. If the trial meets the primary endpoint at completion, then I-Mab holds the potential to have the first CD47 approved in China. That's because, according to talks with Chinese Authorities, this is a registrational trial, which is capable of having a BLA filed should the primary endpoint be met. Thus far, it is a pretty good product in terms of treating patients with hematological malignancies (blood cancers). That is evident by the clinical data achieved to date. About 90 patients with newly diagnosed MDS or acute myeloid leukemia (AML) have received 30 mg/kg Lemzoparlimab in combination with azacitidine (chemotherapy). It was revealed that even without any type of priming dose given to about 50 MDS patients, combination treatment of Lemzoparlimab was very safe/tolerable. It was shown that in terms of MDS patients, there was a >80% objective response rate ((ORR)). With magrolimab and Azacitidine, the combination is comparable to being slightly below this 80% ORR number. Gilead Sciences (GILD) owns magrolimab (CD47 inhibitor) now after buying Forty Seven Inc awhile back. However, I-Mab released updated results at the European Society for Medical Oncology ((ESMO)) Congress 2022 on September 10, 2022 with an oral presentation. For MDS patients receiving a dose of Lemzoparlimab at 3 months, the ORR was 80.6%, and then over 6 months of dosing the ORR rose to 86.7%. The complete response rate in the most recent update was said to be 40%. With this data on hand, it can now push forward to going after high risk MDS patients in the phase 3 study it just received authorization for. Financials According to the 6-K SEC Filing, I-Mab has a cash position of $586 million on hand. It believes that with the current cash on hand, that it could fund its operations for more than 3 years. One thing to keep in mind for this speculative biotech name is that, while its financials are in good order, there is an overhang of an HFCAA delisting. This is not guaranteed, but a possibility because of legislation act holding foreign companies accountable. I believe this is huge risk - as such, I thought it was important to mention this. It should be good on cash for the time being, therefore, I don't see it needing to raise cash in the near-term. I believe what could be possible is if it chooses to raise cash after receiving regulatory approvals in China for one of the BLAs expected in the coming years. Risks To Business There are several risk factors to consider before investing in this biotech. The biggest risk factor would be the overhang of the HFCAA delisting noted above. However, I-Mab states that it has the situation under control by providing shareholders a road map and value to what it intends to do so that it won't be delisted. It believes it can mitigate delisting risks under the HFCAA based on specific steps it has taken in the last 6 months. Despite taking this action, there is still no assurance that it won't face this risk of delisting. It hopes that its current plan of the Statement of Protocol, or a possible contingency plan of changing its auditor should it need to, will accomplish this. The second risk would be with respect to the initiation of the phase 3 registration study, which is using Lemzoparlimab for the treatment of high risk MDS patients. It will take a few years to run this study, and if the primary endpoint is not met, then I-Mab will not be able to file a BLA for approval of this drug in China.Seeking Alpha • Sep 13
I-Mab gets Chinese nod to start phase 3 combo treatment trial for myelodysplastic syndrome
Chinese biotech I-Mab (NASDAQ:IMAB) on Tuesday said it got local regulatory approval to start a phase 3 trial evaluating its antibody lemzoparlimab in combination with cancer drug azacitidine for the treatment of myelodysplastic syndrome (MDS). MDS is a group of cancers caused due to blood cells that are poorly formed or don't work properly. The approval to start the trial follows a successful completion of an end-of-phase 2 meeting with the Center for Drug Evaluation of China's National Medical Products Administration, IMAB said in a statement. The meeting was supported by results from a phase 2 trial assessing lemzoparlimab in combination with azacitidine for the treatment of patients with newly diagnosed higher-risk MS, IMAB said. The company said it is on track to initiate the late-stage study as planned. U.S.-listed shares of IMAB -4.8% at $5.31 in morning trading.Seeking Alpha • Aug 30
I-Mab Biopharma Non-GAAP EPADS of -$1.54, revenue of $7.74M
I-Mab Biopharma press release (NASDAQ:IMAB): 1H Non-GAAP EPADS of -$1.54. Revenue of $7.74M (+181.5% Y/Y).Seeking Alpha • Aug 23
I-Mab and senior executives may buy $40M worth of shares; stock up 10%
I-Mab (NASDAQ:IMAB) and senior management using their own personal funds may purchase up to $40M worth of the company's American Depository Shares on the open market. The buys are part of a share repurchase program previously authorized by the company's board. Shares are up 10% in Tuesday morning trading. See why Seeking Alpha contributor Chris Lacoursiere is bullish on I-Mab (IMAB).Articolo di analisi • Aug 20
Newsflash: I-Mab (NASDAQ:IMAB) Analysts Have Been Trimming Their Revenue Forecasts
Today is shaping up negative for I-Mab ( NASDAQ:IMAB ) shareholders, with the analysts delivering a substantial...Seeking Alpha • Jul 22
I-Mab doses first patient in phase 1 trial of TJ-CD4B in solid tumors in China
I-Mab (NASDAQ:IMAB) said the first patient in China had been treated with its TJ-CD4B in a Phase 1 international multi-center clinical trial for patients with solid tumors, including gastric cancer, gastroesophageal junction carcinoma. TJ-CD4B binds to Claudin 18.2-expressing cancer cells and co-stimulatory molecule 4-1BB on T cells to exert a tumor-killing effect. In March, the U.S. Food and Drug Administration granted Orphan Drug Designation to TJ-CD4B for the treatment of gastric cancer including cancer of gastroesophageal junction.Seeking Alpha • Jun 23
I-Mab Valuation Offers A Biotech Investment Opportunity
The biotech indices have fallen considerably. Many biotechs are trading with negative enterprise values despite unprecedented innovation in the biotech industry. I-Mab is headed for commercialization with enough cash to carry then into 2025 with multiple products hitting the market. I-Mab shares appear significantly undervalued.Articolo di analisi • May 24
Companies Like I-Mab (NASDAQ:IMAB) Are In A Position To Invest In Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Seeking Alpha • May 06
I-Mab Shaken By Management Moves, Merger Talk And Delisting Threat
There’s no shortage of market-moving news these days about up-and-coming cancer drug maker I-Mab, whose stock is getting pulled every which way as a result. The U.S.-China dispute element was in the headlines this week, when I-Mab’s name was added to a U.S. Securities and Exchange Commission list of 88 Chinese firms that could face potential delisting. According to its 2021 annual report, the company has enough capital to fund its operations through 2025, with $671 million in cash combined with expected milestone payments.Articolo di analisi • Apr 01
Bearish: Analysts Just Cut Their I-Mab (NASDAQ:IMAB) Revenue and EPS estimates
The analysts covering I-Mab ( NASDAQ:IMAB ) delivered a dose of negativity to shareholders today, by making a...Seeking Alpha • Jan 03
I-Mab Founder Retakes Reins In Latest Shakeup Ahead Of Commercialization Phase
Four-year company veteran and CEO Joan Shen to depart I-Mab as chairman and founder Zang Jingwu gets set to resume the role. Analysts upbeat as company earmarks 2023 for regulatory approval of key drugs and launch of production facility. Despite that positive outlook, the company’s shares have gone on a rollercoaster ride since listing at $14 in January 2020.Seeking Alpha • Oct 14
I-Mab Gets Boost From Latest Industry Signals On New Cancer Treatment
I-Mab's shares surged up to 15% on positive results from a peer developing a similar new type of cancer treatment, though they later gave back most of those gains. Company has plenty of cash on hand and could soon get more as it seeks a deal to commercialize the drug, uliledlimab, with a U.S. or European partner. Despite I-Mab's recent stock price volatility, many are still quite bullish on the company.AMMINISTRATORE DELEGATO
Srishti Gupta (50 yo)
less than a year
Mandato
Dr. Srishti Gupta, M.D., MPP, is CEO & Director of NovaBridge Biosciences from July 1, 2026. She was CEO & Executive Director of Idorsia Ltd from July 1, 2025 to March 2026. She served as Independent Direc...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Executive Chairman | 8.2yrs | Nessun dato | 2.68% $ 6.2m | |
| Chief Financial Officer | less than a year | Nessun dato | Nessun dato | |
| Chief Business Development Officer & Director | less than a year | Nessun dato | 0.013% $ 30.5k | |
| CEO & Director | less than a year | Nessun dato | Nessun dato | |
| President & Chief Commercial Officer | less than a year | Nessun dato | Nessun dato | |
| Senior Director of Investor Relations | no data | Nessun dato | Nessun dato | |
| General Counsel & Board Secretary | less than a year | Nessun dato | Nessun dato | |
| Senior VP and Head of R&D Center of Excellence | 1.6yrs | Nessun dato | 0.11% $ 259.2k | |
| Chief Medical Officer | 2.2yrs | Nessun dato | 0.059% $ 137.3k |
0.9yrs
Durata media
44yo
Età media
Gestione esperta: Il team dirigenziale di NBP non è considerato esperto (durata media 0.9 anni), il che suggerisce un nuovo team.
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Executive Chairman | 8.2yrs | Nessun dato | 2.68% $ 6.2m | |
| Chief Business Development Officer & Director | 1.3yrs | Nessun dato | 0.013% $ 30.5k | |
| CEO & Director | less than a year | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | 7.2yrs | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | 7.1yrs | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | 7.1yrs | Nessun dato | Nessun dato | |
| Vice Chairman | less than a year | Nessun dato | Nessun dato | |
| Independent Director | 6.6yrs | Nessun dato | 0.099% $ 228.2k | |
| Independent Director | 6.6yrs | Nessun dato | 0.099% $ 228.2k | |
| Member of Scientific Advisory Board | 7yrs | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | 7.1yrs | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | 5.7yrs | Nessun dato | Nessun dato |
6.8yrs
Durata media
61yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di NBP sono considerati esperti (durata media dell'incarico 6.8 anni).
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/08/23 10:14 |
| Prezzo dell'azione a fine giornata | 2026/08/21 00:00 |
| Utili | 2026/06/30 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
NovaBridge Biosciences è coperta da 17 analisti. 2 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Bo Li | BofA Global Research |
| Kumaraguru Raja | Brookline Capital Markets |
| Ziyu He | China International Capital Corporation Limited |